

Innovating science. Inspiring hope.

ADC Therapeutics is Fostering the Future of Cancer
Therapy Through Targeted Antibody Drug Conjugates

At ADC Therapeutics, we strive to transform the lives of those impacted
by cancer by unlocking the potential value of our robust ADC portfolio.

Science

Our platform includes an array of payloads, linkers and conjugation chemistry enabling design of next-gen potent ADCs with an enhanced therapeutic index.

Science

We are seeking expansion of our FDA-approved product, ZYNLONTA®, while pursuing an early-stage solid tumor portfolio.

Pipeline

Medical Affairs

Confronting unmet medical needs in patients with hematologic cancers and solid tumors. There remains significant unmet medical need in cancer therapy. With cancers that recur or are refractory as well as treatments that do not produce durable and complete responses, patients are in need of new approaches across both hematological cancers and solid tumors.

Medical Affairs

Proven Momentum

ZYNLONTA® is a prescription medicine currently approved to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

Learn more



Team

Leadership



Team Partnering Charitable Contributions Sponsorships Contact



Ameet Mallik
Chief Executive Officer

Bio +



Jose Carmona
Chief Financial Officer

Bio +



Peter Graham
Chief Legal Officer

Bio +



Kristen Harrington-Smith
Chief Commercial Officer

Bio +



David Ege, PhD
Chief Technical Officer

Bio +



Kimberly Pope
Chief People Officer

Bio +



Patrick van Berkel, PhD
Chief Scientific Officer

Bio +



Mohamed Zaki, MD, PhD
Chief Medical Officer

Bio +

Board of Directors



Ron Squarer
Chairman

Bio +



Bob Azelby
Non-Executive Director

Bio +



Jean-Pierre Bizzari
Non-Executive Director

Bio +



Peter Hug, PhD
Vice-Chairman and
Lead Independent Director

Bio +



Ameet Mallik
Chief Executive Officer

Bio +



Viviane Monges
Non-Executive Director

Bio +



Thomas Pfisterer
Non-Executive Director

Bio +



Tyrell J. Rivers, PhD
Non-Executive Director

Bio +



Victor Sandor, MD
Non-Executive Director

Bio +

Team

Leadership

Team

Partnering

Charitable Contributions

S

Team

Partnering



Charitable Contributions

Sponsorships

Contact



Ameet Mallik

Chief Executive Officer

Bio +



Jose Carmona

Chief Financial Officer

Bio +



Peter Graham

Chief Legal Officer

Bio +



Kristen Harrington-Smith

Chief Commercial Officer

Bio +



David Ege, PhD

Chief Technical Officer

Bio +



Kimberly Pope

Chief People Officer

Bio +



Patrick van Berkel, PhD

Chief Scientific Officer

Bio +



Mohamed Zaki, MD, PhD

Chief Medical Officer

Bio +

Board of Directors



Ron Squarer

Chairman

Bio +



Bob Azelby

Non-Executive Director

Bio +



Jean-Pierre Bizzari

Non-Executive Director

Bio +



Peter Hug, PhD

Vice-Chairman and
Lead Independent Director

Bio +



Ameet Mallik

Chief Executive Officer

Bio +



Viviane Monges

Non-Executive Director

Bio +



Thomas Pfisterer

Non-Executive Director

Bio +



Tyrell J. Rivers, PhD

Non-Executive Director

Bio +



Victor Sandor, MD

Non-Executive Director

Bio +

Team

Leadership

Team Partnering Charitable Contributions Sponsorships Contact



Ameet Mallik

Chief Executive Officer

Bio -

Ameet Mallik

Chief Executive Officer

Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company.

Prior to Rafael Holdings, Mr. Mallik spent more than 16 years at Novartis where he served as Executive Vice President and Head, U.S. Oncology from November 2017 through April 2021. Prior to this position, Mr. Mallik served Novartis Oncology as Global Head, Marketing, Value and Access, and Head, Latin America and Canada. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial and leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Before working in pharma, Mr. Mallik was an Associate Principal at McKinsey & Company. He currently serves on the boards of directors of ADC Therapeutics and Atara Biotherapeutics.

Mr. Mallik holds an MBA from the Wharton School at the University of Pennsylvania and an MS in Biotechnology and BS in Chemical Engineering, both from Northwestern University.

Close X



David Ege, PhD

Chief Technical Officer

Bio +



Kimberly Pope

Chief People Officer

Bio +



Patrick van Berkel, PhD

Chief Scientific Officer

Bio +



Mohamed Zaki, MD, PhD

Chief Medical Officer

Bio +

Board of Directors



Ron Squarer

Chairman

Bio +



Bob Azelby

Non-Executive Director

Bio +



Jean-Pierre Bizzari

Non-Executive Director

Bio +



Peter Hug, PhD

Vice-Chairman and
Lead Independent Director

Bio +



Ameet Mallik

Chief Executive Officer

Bio +



Viviane Monges

Non-Executive Director

Bio +



Thomas Pfisterer

Non-Executive Director

Bio +



Tyrell J. Rivers, PhD

Non-Executive Director

Bio +



Victor Sandor, MD

Non-Executive Director

Bio +

About ADC Therapeutics

Partnering

[Team](#) [Partnering](#) [Charitable Contributions](#) [Sponsorships](#) [Contact](#)

Our Mission

At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.

To start the conversation about partnering with ADC Therapeutics, please contact us at partnering@adctherapeutics.com. 



About ADC Therapeutics

Charitable Contributions

[Team](#) [Partnering](#) [Charitable Contributions](#) [Sponsorships](#) [Contact](#)

We support charitable causes that aim to help improve the lives of patients and of the communities we serve.



We are committed to supporting external, independent, not-for-profit organizations by funding resources, education, programs and events aimed to improve lives and benefit patient care. These organizations may include patient advocacy groups, professional medical associations, and other charitable organizations.

Charitable Contribution refers to donations to support the general activities of a registered tax-exempt organization engaged in healthcare-related charitable purposes. Please review the application process below for more information.

ADC Therapeutics’ interactive portal accepts unsolicited requests for charitable contributions/donations. The Company will evaluate funding requests monthly for events/activities of registered 501(c)3 tax-exempt organizations engaged in a healthcare-related charitable purpose aligned with ADC Therapeutics’ mission and vision. Requests will also be reviewed for consistency with our corporate objectives and compliance policies. Applicants outside of the U.S. must qualify as a charitable organization within the country where they reside.

This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.

If your request does not fall under this category, we also have portals to evaluate other funding types. See links below or reach out through our contact form(link to contact page):

[Sponsorships/Corporate or State Memberships/Patient Advocacy Grants](#)

[Continuing Medical Education \(CME\) Grants](#)

[Investigator-Initiated Trials \(IITs\)](#)

About ADC Therapeutics

Sponsorships

[Team](#) [Partnering](#) [Charitable Contributions](#) [Sponsorships](#) [Contact](#)

Sponsorships/Memberships/Non-CME Grants

ADC Therapeutics’ interactive portal accepts unsolicited requests for sponsorships, corporate memberships, and non-CME grants that are aligned with ADCT’s mission, vision, and corporate objectives, and are consistent with our compliance policies.

This interactive portal allows you to: 1) provide necessary information so ADCT may appropriately evaluate your request, and 2) track the status of your request.

If your request does not fall under one of the mentioned categories please refer to the following portal or reach out through our [contact form](#).

Charitable Contributions/Donations

Sponsorships/Corporate or State Memberships/Patient Advocacy Grants

Independent Continuing Medical Education Grants

ADC Therapeutics supports independent Continuing Medical Education (CME) grants to support educational activities and programs that assist healthcare professionals in enhancing the care of their patients. ADC Therapeutics’ current area of therapeutic interest is relapsed/refractory diffuse large B-cell lymphoma.

ADC Therapeutics defines a CME grant as a type of grant which consists of funding for activities or initiatives that serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of a healthcare professional (e.g., continuing medical education, continuing health education). These activities may or may not be accredited. The program and content are always decided independently from industry supporters. Likewise, the audience is identified and invited by the recipient organization and not by industry supporters.

The CME grant submission process is done via an interactive portal allowing all requests to come into ADC Therapeutics via a simple, user-friendly website. The portal provides information required to successfully complete your submission and transparently enables you to track the grant’s progress through governance review.

The Grants Review Committee meets regularly to review requests. The status of an individual request is available on the CME grants portal.

[Go to CME Grants portal](#)

Investigator Initiated Trials

ADC Therapeutics and our partners accept unsolicited proposals requesting support to conduct Investigator Initiated Trials (IITs) for our products. Proposals must align with ADC Therapeutics’ strategic areas of interest, including but not limited to:

Clinical interventions assessing unmet medical needs, novel combinations, new indications, and various patient populations in therapeutic areas of interest

Non-interventional studies

Translational and observational studies

Investigators can submit and track the progress of their proposals through the IIT portal. Proposals are reviewed for scientific merit as well as compliance with legal, ethical, and professional obligation prior to endorsement.

Please submit IIT proposals to our partner Sobi for those proposed outside of the United States, excluding Greater China, Singapore and Japan, via their portal.

[Go to IIT portal](#)

[Go to Sobi IIT portal](#)

Request more information

ADC Therapeutics respects the privacy of your personal information. Review our [Privacy Policy](#) for more information. By clicking the SUBMIT REQUEST button below, you indicate that you have read, understand, and agree with the Privacy Policy for the information collected on this form. If you want to stop receiving this information, you may unsubscribe at any time.

* Required Fields

First name*

Last name*

Title

Company/Institution

Email*

Choose one that best describes your industry*

Please choose area(s) of interest*

[Submit request](#)

We respect your privacy and do not tolerate spam and will never sell, rent, lease, or give away your information (name, address, email, etc) to any third party. In addition, we will not send you unsolicited email. [Privacy Policy](#)

Science Focus

Pipeline

Pipeline About ADCs

A robust pipeline of ADCs intended for the treatment of hematological cancers and solid tumors

ADC Therapeutics is advancing a portfolio of investigational ADCs including those which utilize our highly potent pyrrolobenzodiazepine (“PBD”) technology, a differentiated exatecan-based payload with a novel hydrophilic linker and a next generation ADC toolbox.

Pre-clinical candidates targeting Claudin-6, NaPi2b, PSMA and ASCT2 are based on an innovative proprietary approach which utilizes exatecan with a novel hydrophilic linker as a highly potent and differentiated payload.

By leveraging decade-long expertise in the ADC field with multiple INDs and a proven track record of success, ADC Therapeutics continues building this toolbox with new antibody formats, linkers and toxins while advancing a range of payloads, linkers and conjugation technologies against multiple targets to develop differentiated next-generation assets.

The agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.



Hematology

		Preclinical	Phase 1a	Phase 1b	Phase2	Phase 3/ Confirmatory
LOTIS-2 in 3L+ r/r DLBCL ClinicalTrials.gov identifier: NCT03589469 FDA Approved ZYNLONTA® Targeting CD19	Description (+)				FDA Approved	
LOTIS-5 with rituximab in r/r NTE DLBCL ClinicalTrials.gov identifier: NCT04384484 Confirmatory ZYNLONTA® Targeting CD19	Description (+)				Confirmatory	
LOTIS-7 in non-Hodgkin Lymphoma ClinicalTrials.gov identifier: NCT04970901 ZYNLONTA® Targeting CD19	Description (+)					
ADCT-602* Targeting CD22 Acute Lymphoblastic Leukemia ClinicalTrials.gov identifier: NCT03698552	Description (+)					
Claudin-6 Adhesion protein IND-enabling	Description (+)					
PSMA Enzymatic glycoprotein IND-enabling	Description (+)					
NaPi2b Phosphate transporter IND-enabling	Description (+)					
ASCT2 Amino Acid Transporter Drug-candidate selection	Description (+)					

* The ADCT-602 trial is being led by the University of Texas MD Anderson Cancer Center.

Anticipated milestones set forth in this chart are subject to further future adjustment based on, among other factors, the impact of the COVID-19 pandemic.

NTE: Non-Transplant Eligible.

For more information on our clinical trials visit adctmedical.com

Science Focus

Pipeline

Pipeline About ADCs

A robust pipeline of ADCs intended for the treatment of hematological cancers and solid tumors

ADC Therapeutics is advancing a portfolio of investigational ADCs including those which utilize our highly potent pyrrolobenzodiazepine (“PBD”) technology, a differentiated exatecan-based payload with a novel hydrophilic linker and a next generation ADC toolbox.

Pre-clinical candidates targeting Claudin-6, NaPi2b, PSMA and ASCT2 are based on an innovative proprietary approach which utilizes exatecan with a novel hydrophilic linker as a highly potent and differentiated payload.

By leveraging decade-long expertise in the ADC field with multiple INDs and a proven track record of success, ADC Therapeutics continues building this toolbox with new antibody formats, linkers and toxins while advancing a range of payloads, linkers and conjugation technologies against multiple targets to develop differentiated next-generation assets.

The agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.



Hematology

LOTIS-2 in 3L+ r/r DLBCL
ClinicalTrials.gov identifier: NCT03589469
FDA Approved
ZYNLONTA® Targeting CD19

LOTIS-2 in 3L+ r/r DLBCL

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.

Solid Tumors

Claudin-6
Adhesion protein
IND-enabling

PSMA
Enzymatic glycoprotein
IND-enabling

NaPi2b
Phosphate transporter
IND-enabling

ASCT2
Amino Acid Transporter
Drug-candidate selection

* The ADCT-602 trial is being led by the University of Texas MD Anderson Cancer Center.

Anticipated milestones set forth in this chart are subject to further future adjustment based on, among other factors, the impact of the COVID-19 pandemic.

NTE: Non-Transplant Eligible.

For more information on our clinical trials visit adctmedical.com

About ADCs

Delivering on the promise of science by advancing next-generation ADCs

ADC Therapeutics is a pioneer and leader in the antibody drug conjugates (ADCs) field with specialized end-to-end capabilities for developing optimized ADCs. This includes a strong, integrated research & development organization and a validated technology platform, multiple next-generation ADCs being developed and a proven executional track record that includes the first PBD-based ADC receiving accelerated approval from the FDA and conditional approval from the European Commission.

What are ADCs?


Antibody drug conjugates are an established therapeutic approach in oncology. ADCs selectively deliver potent cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells.

Three components


An ADC consists of three components: (i) a **antibody** that selectively targets a distinct antigen preferentially expressed on tumor cells; (ii) a **cytotoxic molecule**, often referred to as the toxin or the warhead, that kills the target cell; and (iii) a **chemical linker** that joins together the antibody and the warhead. The warhead and the linker are together referred to as the payload. The figure below shows the three components of an ADC.

Exatecans belong to the family of camptothecins, which are naturally occurring pentacyclic quinoline alkaloids that bind to DNA topoisomerase I, inhibiting DNA relegation and finally causing apoptosis. Camptothecin, such as exatecan, therefore possess high cytotoxic activity against a variety of tumors.

PBD dimers are highly potent and bind irreversibly to two guanines from opposite DNA strands in the minor groove of DNA without distorting the double helix, potentially evading DNA repair mechanisms. The interstrand cross-links block DNA strand separation, disrupting essential DNA metabolic processes such as replication, and ultimately result in cell death. These interstrand cross-links persist in target cells and can lie dormant, potentially for weeks, which may contribute to the frequency and durability of responses in heavily pre-treated and primary refractory patients that we have observed in our clinical trials with PBD-based ADCs.



ADC Mechanism Of Action



Patient Focus

Clinical Trials

Clinical Trials

Medical Affairs

Early Access

The LOTIS clinical trial program



[402-311] – A Phase 3 Randomized Study of Loncastuximab Tesirine-Ipyl Combined With Rituximab Versus Immunotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

 NCT04384484

 Status: Recruiting

Learn more



A Phase 1b, Open-label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine-Ipyl in Combination With Other Anticancer Agents in Patients with Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)

 NCT04970901

 Status: Recruiting

Learn more



[402-201] – A Phase 2 Open-label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine-Ipyl in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

 NCT03589469

 Status: Active, not recruiting

Learn more



[402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)

 NCT02669017

 Status: Completed

Learn more

Medical Affairs

Confronting unmet medical needs in patients with hematologic cancers and solid tumors

Despite best efforts, there are still cancers that recur or that are refractory; that cause heavily treated patients to fail multiple lines of therapy; and that do not produce a durable and complete response. Following are the diseases that need new approaches to address unmet medical needs in cancer therapy.

Access more resources at [adcmedical.com](#)

Explore our virtual congress experience

[More resources](#)[Virtual Congress](#)

Diffuse Large B-Cell Lymphoma (DLBCL)

Description 

Hodgkin Lymphoma (HL)

Description 

Follicular Lymphoma (FL)

Description 

Marginal Zone Lymphoma (MZL)

Description 

B-Cell Acute Lymphoblastic Leukemia (B-Cell ALL)

Description 

Selected Advanced Solid Tumors

Description 

References: 1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-616. 2. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620 3. Klink AJ, Nabhan C, Lee CH, et al. J Clin Pathways. 2020;6:44-53. 4. ADC Therapeutics doses first patients in pivotal phase 2 clinical trial of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma. News release. BioSpace; October 17, 2019. Accessed March 9, 2021. <https://www.biospace.com/article/adc-therapeutics-doses-first-patients-in-pivotal-phase-2-clinical-trial-of-adct-301-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma/> 5. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019;17(3):166-175. 6. Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, et al. Leuk Lymphoma. 2018;59(4):821-828. doi:10.1080/10428194.2017.1352089 7. Ascierto PA, Butterfield LH, Campbell K, et al. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy). J Transl Med. 2021;19(1):13. doi:10.1186/s12967-020-02627-y

Patient Focus

Medical Affairs

Clinical Trials

Medical Affairs

Early Access

Confronting unmet medical needs in patients with hematologic cancers and solid tumors

Despite best efforts, there are still cancers that recur or that are refractory; that cause heavily treated patients to fail multiple lines of therapy; and that do not produce a durable and complete response. Following are the diseases that need new approaches to address unmet medical needs in cancer therapy.

Access more resources at adcmedical.com

Explore our virtual congress experience

More resources

Virtual Congress

Diffuse Large B-Cell Lymphoma (DLBCL)

Description +

Hodgkin Lymphoma (HL)

Description -

Approximately 15% to 25% of the 16,500 patients diagnosed with HL each year in the U.S. and Europe have relapsed or refractory HL.⁴ While advances have been made in the treatment of HL, a significant unmet medical need remains in the relapsed or refractory HL patient population, especially those who have progressed following treatment with other novel

Follicular Lymphoma (FL)

Description +

Marginal Zone Lymphoma (MZL)

Description +

B-Cell Acute Lymphoblastic Leukemia (B-Cell ALL)

Description +

Selected Advanced Solid Tumors

Description +

References: 1. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. *Am J Hematol*. 2019;94(5):604-616. 2. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620 3. Klink AJ, Nabhan C, Lee CH, et al. *J Clin Pathways*. 2020;6:44-53. 4. ADC Therapeutics doses first patients in pivotal phase 2 clinical trial of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma. News release. BioSpace; October 17, 2019. Accessed March 9, 2021. <https://www.biospace.com/article/adc-therapeutics-doses-first-patients-in-pivotal-phase-2-clinical-trial-of-adct-301-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma/> 5. Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed/refractory acute lymphoblastic leukemia. *Clin Adv Hematol Oncol*. 2019;17(3):166-175. 6. Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, et al. *Leuk Lymphoma*. 2018;59(4):821-828. doi:10.1080/10428194.2017.1352089 7. Ascierto PA, Butterfield LH, Campbell K, et al. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy). *J Transl Med*. 2021;19(1):13. doi:10.1186/s12967-020-02627-y

[Patient Focus](#)

Early Access

[Clinical Trials](#)[Medical Affairs](#)[Early Access](#)

ADC Therapeutics and our partners are committed to confronting cancer with the full potential of its science, bringing unique, targeted therapies and hope to patients and their families. Medical Affairs delivers scientific data and knowledge of the highest scientific and ethical standards to the healthcare community and the patients we serve.

Please submit requests to our partner Sobi for patient access to loncastuximab tesirine (lonca) in countries outside of the United States, excluding Greater China, Singapore and Japan, via their portal at: [Managed Access Programmes | Sobi](#)



ZYNLONTA



Full prescribing information



Go to zynlontahcp.com



Personalized assistance.
Comprehensive support.
One single point of contact.



Coverage Support



Coverage Support

Financial Support



Financial Support

Find out more about our Patient Support Program



Patient Support Program

Investors

[Overview](#) [News](#) [Events and Presentations](#) [Filings](#) [Governance](#) [Stock](#) [Info](#)

Overview

ADC Therapeutics is a leading, commercial-stage global pioneer in antibody-drug conjugates (ADCs). We are focused on unlocking the potential value of our robust ADC pipeline in oncology, with a focus on solid tumors. We are a pioneer in the ADC field with specialized expertise in drug discovery, a validated technology platform, a growing next-generation research pipeline, and a track record of commercial success that includes an approved and marketed product. We aim to accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners.

[Overview](#)[Committee Composition](#)[Leadership Team](#)[Board of Directors](#)

ADCs). We are focused on oncology and have a track record of commercial success and development of

NYSE: ADCT



Price **\$1.83** Change: **-0.07** Volume: **489,568**

Minimum 15 minutes delayed.

Latest News

January 02, 2025

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

December 30, 2024

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Events

December 11, 2024 8:30 AM ET

LOTIS-7 Clinical Trial Update Webcast

Webcast 

December 11, 2024, (opens in new window) November 19, 2024 11:00 AM GMT

LOTIS-7 Clinical Trial Update Webcast

Jefferies London Healthcare Conference

Webcast 

Culture & Careers

Culture & Careers

Culture

Open Positions

At the Center of It All

“Our people are at the heart of everything we do to advance care for cancer patients. Our ADCT team is the most important asset of our company. I am committed to ensuring we provide meaningful health and wellness support so that each employee is at their best both professionally and personally”

Ameet Mallik
Chief Executive Officer

“I believe People are ADCT’s greatest asset. Providing our employees comprehensive benefits stems from the belief that we should consider the physical, mental, emotional, and financial well-being of our team. Not just because it provides a better economic or productivity outcome for the company, but because it’s just the right thing to do if you genuinely care about people”

Kim Pope
Chief People Officer

Vision and Values

As a leading antibody drug conjugate company, we strive to transform the lives of those impacted by cancer

At ADC Therapeutics, our goal is to foster an organization of passionate individuals dedicated to serving our patients. We strive to embody a values-based culture focused on:

Our Values

-
- Integrity ::** Ethical and authentic in our approach
-
- Creativity ::** Innovate with an entrepreneurial spirit
-
- Accountability ::** Ownership to drive results
-
- Collaboration ::** Partner for better outcomes
-
- Urgency ::** Act decisively and proactively

Benefits

Being part of ADC Therapeutics means you are dialed in to a unique and exciting professional opportunity. One important way we demonstrate our commitment to you is through our comprehensive benefits programs.

Compensation & Rewards	List of Benefits
Vacation, Holidays, Sick Leave, Health & Well-Being	List of Benefits
Learning & Development	List of Benefits

US Total Rewards Overview 2025

Learn more about our benefits program.

Download

US Total Rewards Overview 2025



Join us as we strive to transform the lives of cancer patients

View Open Positions

Attention: Search firms/Third-party recruitment agencies

The People team manages the recruiting for all positions at ADC Therapeutics. We will only accept résumés from a search agency/recruiter if we have a signed agreement in place and we have formally requested your help on a specific role. Unsolicited résumés sent to ADCT will be considered property of ADCT. We will not be responsible for any fees associated should we hire from unsolicited résumés.

Please send all emails and requests to recruiting@adctherapeutics.com.

Culture & Careers

Culture

Open Positions

At the Center of It All

“Our people are at the heart of everything we do to advance care for cancer patients. Our ADCT team is the most important asset of our company. I am committed to ensuring we provide meaningful health and wellness support so that each employee is at their best both professionally and personally”

Ameet Mallik

Chief Executive Officer

“I believe People are ADCT’s greatest asset. Providing our employees comprehensive benefits stems from the belief that we should consider the physical, mental, emotional, and financial well-being of our team. Not just because it provides a better economic or productivity outcome for the company, but because it’s just the right thing to do if you genuinely care about people”

Kim Pope

Chief People Officer

Vision and Values

As a leading antibody drug conjugate company, we strive to transform the lives of those impacted by cancer

At ADC Therapeutics, our goal is to foster an organization of passionate individuals dedicated to serving our patients. We strive to embody a values-based culture focused on:

Our Values

- **Integrity ::** Ethical and authentic in our approach
- **Creativity ::** Innovate with an entrepreneurial spirit
- **Accountability ::** Ownership to drive results
- **Collaboration ::** Partner for better outcomes
- **Urgency ::** Act decisively and proactively

Benefits

Being part of ADC Therapeutics means you are dialed in to a unique and exciting professional opportunity. One important way we demonstrate our commitment to you is through our comprehensive benefits programs.

Compensation & Rewards	List of Benefits +
Vacation, Holidays, Sick Leave, Health & Well-Being	List of Benefits -
Learning & Development	List of Benefits +

US Total Rewards Overview 2025

Learn more about our benefits program.

Download

US Total Rewards Overview 2025

US Total Rewards

Overview 2025

Join us as we strive to transform the lives of cancer patients

View Open Positions

Attention: Search firms/Third-party recruitment agencies

The People team manages the recruiting for all positions at ADC Therapeutics. We will only accept résumés from a search agency/recruiter if we have a signed agreement in place and we have formally requested your help on a specific role. Unsolicited résumés sent to ADCT will be considered property of ADCT. We will not be responsible for any fees associated should we hire from unsolicited résumés.

Please send all emails and requests to recruiting@adctherapeutics.com.